• Medientyp: E-Artikel
  • Titel: Antistaphylococcal Activity of CG400549, a New Experimental FabI Inhibitor, Compared with That of Other Agents
  • Beteiligte: Bogdanovich, Tatiana; Clark, Catherine; Kosowska-Shick, Klaudia; Dewasse, Bonifacio; McGhee, Pamela; Appelbaum, Peter C.
  • Erschienen: American Society for Microbiology, 2007
  • Erschienen in: Antimicrobial Agents and Chemotherapy
  • Sprache: Englisch
  • DOI: 10.1128/aac.00550-07
  • ISSN: 0066-4804; 1098-6596
  • Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Pharmacology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>ABSTRACT</jats:title> <jats:p> Among 203 strains of <jats:italic>Staphylococcus aureus</jats:italic> , the MICs of CG400549 were 0.06 to 1.0 μg/ml, with MIC <jats:sub>50</jats:sub> and MIC <jats:sub>90</jats:sub> values of 0.25 μg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 μg/ml). The daptomycin MICs were 0.25 to 2.0 μg/ml for methicillin-susceptible and 0.25 to 4.0 μg/ml against methicillin-resistant strains (including vancomycin-intermediate strains). Single-passage selection testing showed low resistance frequencies with CG400549, but multistep analysis showed that CG400549 yielded resistant mutants after 14 to 17 days in all strains tested. </jats:p>
  • Zugangsstatus: Freier Zugang